McKesson — May 8, 2025 release

These items are generally uncertain and depend on various factors, many of which are beyond the company's control, and as such, any associated estimate and its impact on GAAP performance could vary materially. McKesson anticipates fiscal 2026 Adjusted Earnings per Diluted Share of $36.75 to $37.55 to reflect strong operating momentum across the businesses, strength of its financial position, and a balanced approach to capital deployment. Long-Term Growth Targets McKesson continues to strengthen its portfolio of differentiated assets and capabilities, advancing health outcomes for all. As a result of continued, consistent strong execution against its strategic initiatives, McKesson is updating and reaffirming the following long-term growth targets: • Reaffirming long-term Adjusted Earnings per Diluted Share growth target of 12% to 14%. • Updating U.S. Pharmaceutical long-term Adjusted Segment Operating Profit growth target to 6% to 8% from previous range of 5% to 7%. • Reaffirming Prescription Technology Solutions long-term Adjusted Segment Operating Profit growth target of 11% to 12%. Additional modeling considerations will be provided in the earnings call presentation. Conference Call Details McKesson has scheduled a conference call for today, Thursday, May 8th at 4:30 PM ET to discuss the company’s financial results. The audio webcast of the conference call will be available live and archived on McKesson's Investor Relations website at investor.mckesson.com . Upcoming Inv